aTYR PHARMA annual ebitda
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
aTYR PHARMA EBITDA Growth & History (ATYR)
aTYR PHARMA's calculated EBITDA was −$77.0M for fiscal 2025.
View full aTYR PHARMA company overviewaTYR PHARMA annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$77.0M | −$9.8M | — |
| 2024 | 2024-12-31 | −$67.2M | −$12.9M | — |
| 2023 | 2023-12-31 | −$54.3M | −$8.2M | — |
| 2022 | 2022-12-31 | −$46.2M | −$12.6M | — |
| 2021 | 2021-12-31 | −$33.5M | −$18.2M | — |
| 2020 | 2020-12-31 | −$15.3M | $7.0M | — |
| 2019 | 2019-12-31 | −$22.3M | $9.7M | — |
| 2018 | 2018-12-31 | −$32.1M | $14.4M | — |
| 2017 | 2017-12-31 | −$46.4M | $10.6M | — |
| 2016 | 2016-12-31 | −$57.0M | −$10.3M | — |
| 2015 | 2015-12-31 | −$46.7M | −$24.0M | — |
| 2014 | 2014-12-31 | −$22.7M | −$3.9M | — |
| 2013 | 2013-12-31 | −$18.8M | — | — |
aTYR PHARMA quarterly ebitda
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$10.7M | $9.4M | — |
| Q1 2026 | 2026-03-31 | −$11.3M | $4.3M | — |
| Q4 2025 | 2025-12-31 | −$14.6M | $1.0M | — |
| Q3 2025 | 2025-09-30 | −$26.6M | −$8.6M | — |
| Q2 2025 | 2025-06-30 | −$20.1M | −$3.0M | — |
| Q1 2025 | 2025-03-31 | −$15.6M | $852,000 | — |
| Q4 2024 | 2024-12-31 | −$15.6M | $139,000 | — |
| Q3 2024 | 2024-09-30 | −$18.0M | −$5.5M | — |
| Q2 2024 | 2024-06-30 | −$17.1M | −$3.7M | — |
| Q1 2024 | 2024-03-31 | −$16.5M | −$3.8M | — |
| Q4 2023 | 2023-12-31 | −$15.8M | −$7.9M | — |
| Q3 2023 | 2023-09-30 | −$12.4M | $1.0M | — |
| Q2 2023 | 2023-06-30 | −$13.4M | −$876,000 | — |
| Q1 2023 | 2023-03-31 | −$12.7M | −$410,000 | — |
| Q4 2022 | 2022-12-31 | −$7.9M | $621,000 | — |
| Q3 2022 | 2022-09-30 | −$13.4M | −$5.8M | — |
| Q2 2022 | 2022-06-30 | −$12.5M | −$2.2M | — |
| Q1 2022 | 2022-03-31 | −$12.3M | −$5.2M | — |
| Q4 2021 | 2021-12-31 | −$8.5M | −$3.7M | — |
| Q3 2021 | 2021-09-30 | −$7.6M | −$1.2M | — |
| Q2 2021 | 2021-06-30 | −$10.3M | −$4.2M | — |
| Q1 2021 | 2021-03-31 | −$7.1M | −$9.1M | — |
| Q4 2020 | 2020-12-31 | −$4.8M | $993,000 | — |
| Q3 2020 | 2020-09-30 | −$6.4M | −$1.0M | — |
| Q2 2020 | 2020-06-30 | −$6.2M | −$678,000 | — |
| Q1 2020 | 2020-03-31 | $2.0M | $7.7M | — |
| Q4 2019 | 2019-12-31 | −$5.8M | −$21,000 | — |
| Q3 2019 | 2019-09-30 | −$5.3M | $1.1M | — |
| Q2 2019 | 2019-06-30 | −$5.5M | $4.3M | — |
| Q1 2019 | 2019-03-31 | −$5.7M | $4.3M | — |
| Q4 2018 | 2018-12-31 | −$5.8M | $5.3M | — |
| Q3 2018 | 2018-09-30 | −$6.5M | $4.2M | — |
| Q2 2018 | 2018-06-30 | −$9.8M | $2.0M | — |
| Q1 2018 | 2018-03-31 | −$10.0M | $2.9M | — |
| Q4 2017 | 2017-12-31 | −$11.0M | $1.3M | — |
| Q3 2017 | 2017-09-30 | −$10.7M | $3.0M | — |
| Q2 2017 | 2017-06-30 | −$11.7M | $3.5M | — |
| Q1 2017 | 2017-03-31 | −$13.0M | $2.9M | — |
| Q4 2016 | 2016-12-31 | −$12.3M | $4.0M | — |
| Q3 2016 | 2016-09-30 | −$13.6M | −$2.6M | — |
| Q2 2016 | 2016-06-30 | −$15.2M | −$4.5M | — |
| Q1 2016 | 2016-03-31 | −$15.9M | −$7.2M | — |
| Q4 2015 | 2015-12-31 | −$16.3M | −$10.4M | — |
| Q3 2015 | 2015-09-30 | −$11.1M | −$5.1M | — |
| Q2 2015 | 2015-06-30 | −$10.7M | −$5.5M | — |
| Q1 2015 | 2015-03-31 | −$8.7M | −$3.0M | — |
| Q4 2014 | 2014-12-31 | −$5.8M | — | — |
| Q3 2014 | 2014-09-30 | −$6.0M | — | — |
| Q2 2014 | 2014-06-30 | −$5.2M | — | — |
| Q1 2014 | 2014-03-31 | −$5.7M | — | — |
aTYR PHARMA ebitda trends
Over the last five fiscal years, aTYR PHARMA's ebitda decreased from −$15.3M to −$77.0M, a change of −$61.6M. The latest reported quarter, Q2 2026, shows −$10.7M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review aTYR PHARMA source filings ↗Community posts
aTyr outlines a new Phase 3 sarcoidosis study after FDA discussions
aTyr Pharma ($ATYR) said it had aligned with the FDA on the design of a Phase 3 study of efzofitimod in pulmonary sarcoidosis patients with restrictive lung disease. The planned trial would enroll 372 patients and compare treatment with pla ...
